Free Shipping in the U.S. for orders over $1000.  Shop Now>>

Recombinant p57Kip2 (Mitotic Inhibitor/Suppressor Protein) Antibody [KIP2/7083R]

In Stock
Catalog Number Formulation Size Price
1028-RBM5-P0
Purified Ab with BSA and Azide at 200ug/ml
20ug
$229.00
1028-RBM5-P1
Purified Ab with BSA and Azide at 200ug/ml
100ug
$519.00
1028-RBM5-P1ABX
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
100ug
$519.00
Flat Rate Domestic: $75 | Orders outside the US - Contact Us for Order Information | Ships next business day

Applications & Dilutions

Applications Tested Dillution Protocol Note
Immunohistochemistry (IHC)
1-2ug/ml
30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes

Summary

Recognizes a protein of 57kDa, identified as p57Kip2. It shows no cross-reaction with p27Kip1. p57Kip2 is a potent tight-binding inhibitor of several G1 cyclin complexes, and is a negative regulator of cell proliferation. Anti-p57 has been used as an aide in identification of complete hydatidiform mole (CHM) (no nuclear labeling of cytotrophoblasts and stromal cells) from partial hydatidiform mole (PHM) in which both cytotrophoblasts and stromal cells stain. The histological differentiation of complete mole, partial mole, and hydropic spontaneous abortion is problematic. Most complete hydatidiform moles are diploid, whereas most partial moles are triploid. Ploidy studies will identify partial moles, but will not differentiate complete moles from non-molar gestations. Complete moles carry a high risk of persistent disease and choriocarcinoma, while partial moles have a very low risk. In normal placenta, many cytotrophoblast nuclei and stromal cells are labeled with this antibody. Similar findings apply to PHM and hydropic abortus tissues. Intervillous trophoblastic islands (IVTIs) demonstrate nuclear labeling in all three entities and serve as an internal control.

Product Properties & Targets

Host
Rabbit
Applications
Species Reactivity
Isotype / Light Chain
IgG / Kappa
Cellular Localization
Nucleus
Gene Name
Positive Control
HT29 or SK-BR3 cells. Human colon or prostate carcinomas., Raji
Immunogen
Recombinant full-length human p57Kip2 protein
Alternate Names
Cyclin-dependent kinase inhibitor 1C, Cyclin-dependent kinase inhibitor p57, p57Kip2, Beckwith Wiedemann syndrome (WBS); BWCR; Cyclin dependent kinase inhibitor 1C (CDKN1C); KIP2; p57

Database Links

Entrez Gene ID
SwissProt

Additional Information

Clone
KIP2/7083R
Chromosome Location
11p15.5
Mol. Weight of Antigen
57kDa

Functions

  • Potent tight-binding inhibitor of several G1 cyclin/CDK complexes (cyclin E-CDK2, cyclin D2-CDK4, and cyclin A-CDK2) and, to lesser extent, of the mitotic cyclin B-CDC2. Negative regulator of cell proliferation. May play a role in maintenance of the non-proliferative state throughout life.

Key References

  • Lee, M.-H., et al. 1995. Cloning of p57, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 9: 639-649.

Storage & Stability

Antibody with azide - store at 2 to 8 °C. Antibody without azide - store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Limitations

This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Warranty

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

Reviews

There are no reviews yet.

Be the first to review “Recombinant p57Kip2 (Mitotic Inhibitor/Suppressor Protein) Antibody”

Your email address will not be published. Required fields are marked *

PARTNERSHIP OPPORTUNITIES

NeoBiotechnologies holds Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK